The State of Market Access in Italy 2023

A Report from the 21st Conferenza Nazionale Sulla Farmaceutica: Interview with Giovanni Firenze, Director, Market Access Italy, Alira Health

In Italy today, companies that are striving to get new drugs to market and into the hands of patients face many challenges. To learn about the state of market access in Italy today, we spoke with Giovanni Firenze, Director of Market Access Italy for Alira Health, who attended the recent 2023 Conferenza Nazionale Sulla Farmaceutica at the University of Catania. The theme of the event was “Access to Medicines: The Problems on the Table.”

Giovanni has thirty years of experience in pharmaceutical companies and life sciences consulting. He holds an MSE in Mechanical Engineering with an emphasis in business and project management from the University of Genoa and a joint MBA from the SDA Bocconi and the University of Michigan.

Published on:
March 20, 2023
Written by:
Giovanni Firenze
If the regions are willing to forego the process of re-evaluating drugs and instead concentrate on how they can best get treatments to patients, everyone involved will benefit.
Giovanni Firenze Director of Market Access Italy, Alira Health
The event’s theme cited the problems on the table for market access in Italy. What is the most significant problem?

Definitely one of the most significant problems companies are facing in Italy is the issue of EUnetHTA, which will become official in 2025, creating one system to evaluate drugs across the EU. The question is, what are the implications of EUnetHTA for the Italian health system? What will the relationship be between Agenzia Italiana del Farmaco (AIFA)’s current processes and the new EUnetHTA processes? Everyone across Europe is asking, how different from my current domestic process will EUnetHTA be? Coming out of this conference, the prediction is that the AIFA model will not be too different from EUnetHTA. However, there was a lot of discussion around comparators, which will be a key difference. At the European Medicines Agency (EMA), like the Food & Drug Administration (FDA) in the U.S., they are focused on a risk-benefit analysis; if a drug offers more benefits than risks, the drug will be approved. At the domestic level in Italy, AIFA compares a new drug against available drugs (comparators) that are considered the Standard of Care (SOC). So that’s a very different focus.

Reimbursement for drugs is often a barrier to market access; is this true in Italy today?

Yes, absolutely. The challenge is that the there are two reimbursement processes in Italy – national reimbursement as part of AIFA’s approval, and the inclusion of new medicines in the regional list of drugs. So, a company can successfully go through the process of evaluation and approval with AIFA, including agreement for reimbursement at a specific price. But then you have to get market access at a regional level, which is not only a new battle but also a more complicated one. Italy has 20 regions, and most have their own approach. Plus, the regions each go through their own process of evaluating a drug. This decision is misguided because the AIFA evaluation is extremely thorough, looking at three points: unmet medical needs, added therapeutic value, and quality of clinical trial data. This is a unique approach – many other HTAs do not look at data quality in-depth. So the regional evaluation is pointless, and only serves to delay patient access to the drug. The AIFA evaluation takes 12 – 15 months, and then the regional process can take up to 15 months. So sometimes, it could be up to 30 months before a drug can reach the market, depending on the region.

The consensus coming out of the conference is that the regions should consider these questions: What resources are available to us? What are the prescription models adopted here? What are the distribution models here? What are the models for purchasing within our region? If the regions focused on these supply chain components rather than on evaluating drugs, which has already been done in great detail by AIFA, the time to market could be greatly reduced. The key is to educate stakeholders and regional leaders to increase understanding of this dilemma and the resulting delay in market access. If the regions are willing to forego the process of re-evaluating drugs and instead concentrate on how they can best get treatments to patients, everyone involved will benefit.

Pricing can also slow down market access; what’s the latest on that front?

Pricing presented another interesting topic of discussion at Conferenza Nazionale Sulla Farmaceutica; in particular, possible new models to be adopted for pricing and reimbursement of pharmaceutical drugs based on lifecycle stage. Today, a company will negotiate price and reimbursement with AIFA while launching a new product; later, if they add a new indication to that drug, they must renegotiate, and AIFA usually asks that they lower the price. Pharma companies want to change this because they feel that they are adding value to the product and should not have to lower the price. Instead of talking about volume discounts, pharmas want to switch to a model which attaches the price to the value of the product for that specific indication. In this scenario, a new indication would be evaluated and priced separately from the original drug, and the price would correspond to the indication. This is just one proposal that’s under discussion; the goal right now is to create awareness of this issue.

Was the topic of Early Access Programs (EAPs) in Italy under discussion at the conference?

Yes, EAPs were a hot topic. Italy currently has five different EAPs – Law 648/96, Cnn, Law 94/96, Fund 5%, and Compassionate Use, all mainly focused on providing access to drugs for rare and ultra-rare diseases. The outcome of the discussion at Conferenza Nazionale Sulla Farmaceutica was that EAPs do present opportunities, but currently, the major problem is that the money available from these EAPs is very limited. For example, if you have an ultra-rare disease drug in a Phase II trial which seems to qualify for reimbursement, even if you comply with all the rules of the EAP in question, you might not receive reimbursement because the program doesn’t have enough money. Another problem is that the program eligibility is not clear, the rules are complex and confusing, and if you are rejected, it’s difficult to know why. A major focus among all healthcare stakeholders should be on improving the clarity of the EAPs and their requirements. And at the government level, the issue of effectively funding the EAPs must be addressed.

Were there any other calls to action coming out of the conference?

The healthcare industry is one of the most important for the Italian economy, and it receives the highest amount of global investment in the country, creating a positive impact on the Italian Gross Domestic Product (GDP). This was very clear immediately after COVID-19, because investments had to be made in the whole healthcare system – and the GDP increased significantly as a result, as presented by Massimo Scaccabarozzi during the last day of conference. So the call to action is, let’s invest more in Italian healthcare companies because that generates value for the overall Italian economy.

How can Alira Health’s market access team help pharmaceutical companies to manage market access issues in Italy?

We can help by keeping you up-to-date on the latest developments at the EU and AIFA levels, including EUnetHTA and how you might need to adjust to a risk-benefit analysis approach to approvals. We advise clients on the best approach to reimbursement at the national and regional levels and advocate for policy change to better streamline the process and get products to market faster. If your drug targets a rare disease, we can also work with you on navigating the challenging EAPs that are available in Italy. Market access is a slow process in Italy, but we are here to help you move through it as fast as possible to get treatments in the hands of patients.

Related news

Blog November 17, 2023
Misconceptions About Patient-Centric Co-Design
Many people have misconceptions about patient-centric co-design, and these misconceptions are holding companies back.
Co-Design Digital Health MedTech Patient Centricity Pharma
Publications November 14, 2023
Capture of CH1-Containing Bispecific Antibodies: Evaluating an Alternative to Protein A
In the article our team investigated the use of an alternative purification method for BsAbs – a commercially available CaptureSelect CH1-XL affinity resin.
CMC Drug Development
Events November 8, 2023
Spain Healthcare Innovation Summit
We will sponsor and speak at Spain Healthcare Innovation Summit, a premier event that brings together healthcare professionals from across Spain and beyond to discuss the latest developments(...)
Market Access Patient Centricity Spain
Blog November 2, 2023
The Impact of New Treatment Approvals in Oncology on Relative Survival Rates for EU Patients
This article explores the relationship between the number of new cancer treatment approvals and the five-year relative survival of cancer patients across the European Union (EU).
Oncology Pharma
Blog October 16, 2023
Biotechs on the Rise
In the final article of our Biotech series, Joris Pezzini talks about the evolution of biotechs in the face of challenges and the drivers for future success.
Biotech Drug Development
Blog October 16, 2023
How to Co-Design a Solution with Patients to Meet Their Needs
To learn how you can benefit from a co-design approach and how to get started, we spoke with two experts on patient engagement and co-design.
Digital Health MedTech Patient Centricity Patient Engagement Pharma
Events October 15, 2023
CPHI Barcelona
Connect with us at CPHI in Barcelona and learn how we design tailor-made solutions to achieve your business goals at every step of the way.
Market Access Spain Transaction Advisory
Welcome to Alira Health. This site is best viewed in Chrome, Microsoft Edge, or Firefox.